| Name | Title | Contact Details |
|---|
XLI is a full service manufacturer of precision engineered mechanical components and complex electro-mechanical subassemblies for applications including motorized vehicles, firearms, security instrumentation and communications. XLI manufactures your product according to your specifications and delivery requirements on a repetitive, low volume production basis in our U. S. facilities. Our organization provides complete customer support from engineering to manufacturing to product testing, packaging and delivery to streamline your procurement effort and expense.
Livspace is one of the largest and fastest-growing home interiors and renovation companies. Using its proprietary technology, Livspace provides a one-stop renovation solution for homeowners—from design to managed last mile fulfillment for all rooms in a home. The Brand Has organized a fragmented industry, bringing together designers, brands, manufacturers and contractors to enable an eCommerce-like trusted and predictable experience. Livspace currently serves the Middle East, and Singapore, as well as 50+ metro and non-metro areas in India. Livspace has showcased phenomenal growth since its launch, having delivered over 120,000 rooms and selling over 5 million SKUs through its platform. The company has raised around USD 450 million in capital from some of the top global investors including KKR, Ingka Group Investments (part of largest IKEA retailer Ingka Group), TPG Growth, Goldman Sachs, Kharis Capital, Venturi Partners, FFP (Peugeot Groups Holding Company), EDBI, Bessemer Venture Partners, Jungle Ventures, Helion Ventures and UC-RNT.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
A collective of category-defining maker brands redefining what is humanly possible in the outdoors.